



## Redsense Medical reinforces the team with a new Chief Technology Officer

Redsense Medical has signed an agreement with Ann-Marie Eriksson, who will be the Company's new Chief Technology Officer. When Ann-Marie joins the Company, she will be responsible for leading the R&D projects, a key task as the Company continues to develop its blood loss detection technology into a comprehensive solution for smart wound care adapted to meet the demands of the future. As the new CTO, she will also be responsible for managing the Company's regulatory work relating to quality systems, and for securing input to the Company's supply chain – a critical area, especially in view of the Company's expansion strategy to intensify and accelerate sales, with a particular focus on the rapidly growing US market, and to strengthen the supply chain to handle larger volumes.

*"Redsense is a very exciting company, with great future prospects and a technology that may prove disruptive to the global wound care market. I look forward to doing my bit to turn that vision into reality, and I am very pleased to be able to contribute with my knowledge and experience in this important stage of the Company's journey," says Ann-Marie Eriksson.*

Ann-Marie Eriksson holds a M.Sc. in Electrical Engineering with specialization in signal processing and telecommunications from the Chalmers University of Technology. Her most recent position was at the Halmstad branch of Etteplan Sweden AB, Swedish subsidiary of the international engineering group Etteplan, where she has led the team successfully as Department Manager, Area Manager and Teamleader. She has solid experience of project management and quality systems management, with particular expertise in medical devices.

*"We are positively thrilled to be able to welcome Ann-Marie to our team. Her significant experience from project management and regulatory frameworks in the context of medical devices is a valuable addition to Redsense. Ann-Marie provides the Company with unique new qualities, and she will play a pivotal role in our ongoing technology development and sales expansion," says Patrik Byhmer, CEO of Redsense Medical AB.*

*For more information, please contact:*

Patrik Byhmer, CEO Redsense Medical AB (publ)

Phone: +46 35 10 60 30

[info@redsensemecal.com](mailto:info@redsensemecal.com)

[www.redsensemecal.com](http://www.redsensemecal.com)

### ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.